34.56

0.95% -0.33

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $34.56, with a volume of 600.55K. It is down -0.95% in the last 24 hours and down -14.58% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Previous Close:

$34.89

Open:

$35.14

24h Volume:

600.55K

Relative Volume:

1.17

Market Cap:

$1.97B

Revenue:

$681.88M

Net Income/Loss:

$122.63M

P/E Ratio:

16.38

EPS:

2.11

Net Cash Flow:

$220.18M

1W Performance:

-11.34%

1M Performance:

-14.58%

6M Performance:

-6.09%

1Y Performance:

+4.73%

1-Day Range:

$33.97

$35.30

1-Week Range:

$33.97

$39.50

52-Week Range:

$28.14

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1169)

Industry

Biotechnology (678)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

246

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	34.56	1.97B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

05:10 AM

Harmony Biosciences to Announce Q4 & Full Year 2024 Results on February 25, 2025 - MSN

05:10 AM

Feb 20, 2025

Harmony Biosciences (NASDAQ:HRMY) Receives Buy Rating from HC Wainwright - MarketBeat

Feb 20, 2025

Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down After Analyst Downgrade - MarketBeat

Feb 20, 2025

‘Short-Tem Setback’ for Harmony Biosciences in Idiopathic Hypersomnia Application for Pitolisant - Sleep Review

Feb 20, 2025

Harmony Biosciences price target cut to $42 at Mizuho - Investing.com

Feb 20, 2025

Harmony Biosciences Faces Regulatory Setback, Outlines Future Plans for Pitolisant - MyChesCo

Feb 20, 2025

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider.com

Feb 20, 2025